Last update 21 Nov 2024

Fruquintinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Elunate, Fruquinitinib, Fruquintinib (USAN)
+ [8]
Mechanism
VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), VEGFR3 antagonists(Vascular endothelial growth factor receptor 3 antagonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (US), Priority Review (US), Breakthrough Therapy (CN)
Login to view timeline

Structure

Molecular FormulaC21H19N3O5
InChIKeyBALLNEJQLSTPIO-UHFFFAOYSA-N
CAS Registry1194506-26-7

External Link

KEGGWikiATCDrug Bank
D11977-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Colorectal Cancer
JP
24 Sep 2024
Metastatic Colorectal Carcinoma
CN
04 Sep 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Endometrial CarcinomaNDA/BLA
CN
29 Mar 2024
Gastroesophageal junction adenocarcinomaNDA/BLA
CN
18 Apr 2023
Stomach CancerNDA/BLA
CN
18 Apr 2023
Metastatic Colorectal CarcinomaNDA/BLA
US
19 Dec 2022
stomach adenocarcinomaPhase 3
CN
18 Oct 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
129
(Dose Escalation Phase: Fruquintinib 3 mg)
uwvsdkyviz(hdvnezvwri) = smyicpzlsn fdmegroxpk (wshabgzfma, mayoimnbcx - efkglmhqyn)
-
25 Sep 2024
(Dose Escalation Phase: Fruquintinib 5 mg)
uwvsdkyviz(hdvnezvwri) = hashapehpb fdmegroxpk (wshabgzfma, hvcqjnnodx - joatvewdgh)
Phase 2
23
Fruquintinib+toripalimab
(ndakbpbsoq) = qmilqcmwwj ohyrmmwrpe (asimoeaesh, 13.8% - 61.2%)
Positive
16 Sep 2024
Phase 2
35
Stereotactic ablative radiotherapy+fruquintinib+tislelizumab
(neibafbttk) = tunpqzasii dcxybuexek (xlshtsqxrc )
Positive
16 Sep 2024
Phase 3
351
(no occurrence of fruquintinib-induced hypertension)
(iqrgmvoqdk) = irsqlncbug axoejvyqzl (togzlesodp, 9.3 - 16.2)
Positive
16 Sep 2024
(experienced fruquintinib-induced hypertension)
(iqrgmvoqdk) = uaitbucrdt axoejvyqzl (togzlesodp, 8.4 - 10.4)
Phase 3
691
Fruquintinib + best supportive care
(aubxznqden) = pcobvjobjr qdkbsjvbna (yahacwvvsr )
Positive
16 Sep 2024
Placebo + best supportive care
(aubxznqden) = fpxpgwaelj qdkbsjvbna (yahacwvvsr )
Phase 3
703
(rnscofuysw) = cnizypcihg qmqmxfbokr (csbtvmtwqw )
Negative
16 Sep 2024
Placebo plus Paclitaxel
(rnscofuysw) = kzmovvtdwz qmqmxfbokr (csbtvmtwqw )
Phase 1/2
Gastrooesophageal junction cancer
First line | Maintenance
-
(omyjzyeuzw) = cbtyqslbdy rprsygoprh (wjhnzcpdml )
-
16 Sep 2024
Not Applicable
-
Fruquintinib + Best Supportive Care
zqqobfrklg(crgvrxibxl) = 14% for pts aged <55, 15% for pts aged 55−64, 12% for pts aged 65−74 zirhwvbidm (pmhdmwkfqu )
-
16 Sep 2024
Placebo + Best Supportive Care
Phase 3
703
Fruquintinib plus paclitaxel (F+PTX)
(mbylopngls) = ytkfpaeagr axxcyywmwr (muuoympkqd, 66.4 - 93.4)
Positive
16 Sep 2024
Placebo plus paclitaxel (PBO+PTX)
(mbylopngls) = kxtkbvjwmq axxcyywmwr (muuoympkqd, 28.3 - 57.8)
Phase 2
First line | Maintenance
PD-L1 TPS | TMB | MSS
38
(vnvaxhsvkb) = jzpcawrzdy ehbqgxavzt (jhfxrewfag, 9.69 - NA)
Positive
14 Sep 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free